The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 353:1182-1183 September 15, 2005 Number 11
NextNext

Peginterferon Alfa-2b and Ribavirin for 12 versus 24 Weeks in HCV Infection

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Mangia, A.
-PubMed Citation
To the Editor: Mangia and coworkers (June 23 issue)1 report that the course of combination therapy can be shortened from 24 to 12 weeks with minimal loss of efficacy in patients infected with hepatitis C virus (HCV) genotype 2 or 3 who have early clearance of HCV RNA. Nevertheless, three issues should be considered before these findings in patients in Italy can be extrapolated to U.S. patients.

First, the study used doses of peginterferon alfa-2b (1.0 µg per kilogram of body weight per week) and ribavirin (1000 or 1200 mg daily) that differ from those usually recommended in the United . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.